Printer Friendly

GALAGEN NAMES TWO SENIOR SCIENTISTS

 MINNEAPOLIS, Feb. 8 /PRNewswire/ -- GalaGen, Inc. today announced it has elected Robert A. Hoerr, M.D., Ph.D., to the newly created position of vice president, medical and regulatory affairs; and has named Peter L. Sadowski, Ph.D., a senior research scientist.
 Jack Sheppard, chairman and CEO of GalaGen, said, "Bob Hoerr and Pete Sadowski have broad backgrounds in clinical research and development that will be great assets to GalaGen as we move toward regulatory approval of our biopharmaceutical product portfolio. Expanding our management team with two individuals having such high- quality, relevant experience is critical to GalaGen's commercial success."
 Hoerr had been director, medical affairs for Sandoz Nutrition Corp., Minneapolis, where he developed and managed the company's clinical research programs focused on enteral nutrition and obesity. His responsibilities at Sandoz included design, execution and analysis of clinical trials and support of product commercialization efforts, as well as serving as liaison with the FDA and other regulatory agencies. He also represented Sandoz at congressional investigative hearings and at scientific review panels for the National Institutes of Health.
 Prior to joining Sandoz, Hoerr was a research scientist and assistant program director at the Clinical Research Center, Massachusetts Institute of Technology (MIT), Cambridge, Mass. He received a Ph.D. in biochemistry and metabolism from MIT, and an M.D. from the Indiana University School of Medicine, Indianapolis. He is a diplomate of the American Board of Internal Medicine, and a member of the American College of Physicians, the American Medical Association, and the American Society for Enteral and Parenteral Nutrition.
 Peter L. Sadowski had been vice president, research and development for American Biosystems, Inc., Stillwater, Minn. He was part of the original management team that took the company from inception to FDA approval of its first medical product and sales of more than $2 million. Prior to that, he was director of immunology and clinical research for Molecular Genetics, Inc., Minnetonka, Minn., where he served more than seven years. From 1977 to 1980, he was a staff fellow in the Laboratory of Microbial Structure and Function, Rocky Mountain Laboratories, Hamilton, Montana. Sadowski received a Ph.D in microbiology from the University of Minnesota, Minneapolis.
 GalaGen, based in the Twin Cities suburb of Arden Hills, was formed in March 1992. The company currently has three milk- and colostrum- based immunoglobulin (MCBI) products in clinical trials, and two in late-stage preclinical development. GalaGen's orally delivered MCBI products address cryptosporidiosis (an intractable diarrhea occurring in HIV/AIDS sufferers), gastric ulcers and several other infectious diseases of the digestive tract.
 -0- 2/8/93
 /CONTACT: John Swenson of Swenson Falker Eilertsen Inc., 612-371-0000, for GalaGen/


CO: GalaGen, Inc. ST: Minnesota IN: MTC SU: PER

KH -- MN013 -- 4216 02/08/93 15:23 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 8, 1993
Words:457
Previous Article:HILTON HOTELS NAMES RAYMOND C. AVANSINO JR. PRESIDENT AND CHIEF OPERATING OFFICER
Next Article:NETWORK SYSTEMS ANNOUNCES FOURTH QUARTER EARNINGS OF $.20 PER SHARE BEFORE RESTRUCTURING CHARGE
Topics:


Related Articles
NEWLY FORMED GALAGEN INC. TO DEVELOP BIOPHARMACEUTICALS FROM MILK
WALLIN TO JOIN GALAGEN BOARD
GALAGEN SIGNS TECHNOLOGY LICENSING AGREEMENT WITH NESTLE S.A.
GALAGEN INC. NAMES DR. ROBERT A. HOERR PRESIDENT AND COO
GALAGEN'S SPORIDIN-G QUALIFIES FOR ORPHAN DRUG DESIGNATION
GalaGen Inc. Announces Appointment of Mr. Frank Kuhar as New Chief Financial Officer.
Immune milk products for treating infectious diseases.
GalaGen Reports First Quarter Results.
GalaGen Reports Second Quarter Results and Sale of Critical Care Nutrition Products Business.
GalaGen Reports Third Quarter Results.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters